CRVS · Nasdaq · CIK 0001626971

Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc.’s most recent SEC filing in our snapshot is a Form SCHEDULE 13G filed on Aug 7, 2026. Its EDGAR record lists 12 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
—
Net income, FY2025
-$15.3M
Form 4 filings on record, past 12 months
12

Company overview

Legal name (as filed)
Corvus Pharmaceuticals, Inc.
Ticker
CRVS
SEC Central Index Key (CIK)
0001626971
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
SOUTH SAN FRANCISCO, CA
State or country of incorporation
DE
Fiscal year ends
December 31
SEC filer category
Non-accelerated filer<br>Smaller reporting company
Position in SEC ticker list
#2515 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Corvus Pharmaceuticals, Inc.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
n/aFY2021n/aFY2022n/aFY2023n/aFY2024n/aFY2025
Net income
-$43.2MFY2021-$41.3MFY2022-$27.0MFY2023-$62.3MFY2024-$15.3MFY2025
CRVS annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue—————
Net income-$43.2M-$41.3M-$27.0M-$62.3M-$15.3M
Diluted EPS-$1.03-$0.89-$0.56-$1.02-$0.53
Total assets$109.5M$68.2M$45.6M$68.9M$71.1M
Cash and equivalents$63.5M$13.2M$12.6M$8.7M$4.6M

XBRL tags used: netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

CRVS latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 12, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 6, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 6, 20268-KResults of operations· period Aug 6, 2026Document · Index
Apr 24, 2026DEF 14ADefinitive proxy statement· period Jun 11, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Corvus Pharmaceuticals, Inc., by form type:

8-K ×104 ×8SCHEDULE 13G/A ×5SCHEDULE 13G ×3424B5 ×310-Q ×2SCHEDULE 13D/A ×23 ×1S-8 ×1DEFA14A ×1DEF 14A ×1S-3ASR ×110-K ×1S-3MEF ×1
CRVS recent filings
FiledFormWhat it isOriginal
Aug 7, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Aug 6, 20268-KResults of operations· period Aug 6, 2026Document · Index
Aug 6, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Jul 27, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jul 22, 20268-KDirector or officer change· period Jul 21, 2026Document · Index
Jun 15, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 11, 2026Document · Index
Jun 15, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 11, 2026Document · Index
Jun 15, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 11, 2026Document · Index
Jun 15, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 11, 2026Document · Index
Jun 15, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 11, 2026Document · Index
Jun 12, 20268-KShareholder vote results· period Jun 11, 2026Document · Index
May 20, 20264Statement of changes in beneficial ownership (insider trade)· period May 18, 2026Document · Index
May 15, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
May 15, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
May 14, 20268-KRegulation FD disclosure; Other events· period May 14, 2026Document · Index
May 7, 20268-KResults of operations· period May 7, 2026Document · Index
May 7, 2026S-8Registration of employee benefit plan securitiesDocument · Index
May 7, 202610-QQuarterly report· period Mar 31, 2026Document · Index
Apr 27, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Apr 27, 20264Statement of changes in beneficial ownership (insider trade)· period Apr 23, 2026Document · Index
Apr 27, 20263Initial statement of beneficial ownership· period Apr 23, 2026Document · Index
Apr 24, 2026DEFA14AAdditional proxy soliciting materialsDocument · Index
Apr 24, 2026DEF 14ADefinitive proxy statement· period Jun 11, 2026Document · Index
Apr 23, 20268-KDirector or officer change· period Apr 22, 2026Document · Index
Mar 26, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Mar 13, 20268-KMaterial agreement· period Mar 13, 2026Document · Index
Mar 13, 2026424B5424B5Document · Index
Mar 13, 2026S-3ASRSimplified registration statementDocument · Index
Mar 12, 20268-KResults of operations· period Mar 12, 2026Document · Index
Mar 12, 202610-KAnnual report· period Dec 31, 2025Document · Index
Feb 13, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Feb 5, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Jan 30, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 28, 2026Document · Index
Jan 30, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Jan 27, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Jan 23, 20268-KOther events· period Jan 21, 2026Document · Index
Jan 23, 2026424B5424B5Document · Index
Jan 21, 2026S-3MEFS-3MEFDocument · Index
Jan 20, 2026424B5424B5Document · Index
Jan 20, 20268-KOther events· period Jan 20, 2026Document · Index

Insider filing activity

12 Form 4 filings appear in Corvus Pharmaceuticals, Inc.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations· Companies headquartered in California

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001626971 and XBRL company facts. Corvus Pharmaceuticals, Inc. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.